Home > Insider Trading > Filing (0000950170-24-014017)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1788028	Jasper Therapeutics Inc.	JSPR	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
933790	Tc Group, Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1354120	Carlyle Investment Management Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1397144	Llp Abingworth	38 Jermyn Street London, England X0 SW1Y 6DN	No	No	No	No
1527166	Carlyle Group Inc.	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1548626	Carlyle Holdings I Gp Inc.	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1548627	L.l.c. Sub Gp I Holdings Carlyle	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1548628	L.p. I Holdings Carlyle	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1688313	Abingworth Bioventures Vii Lp	38 Jermyn Street London, England X0 SW1Y 6DN	No	No	No	No
1790577	L.l.c. Holdings Subsidiary Cg	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No
1941860	Carlyle Genesis Uk Llc	C/O The Carlyle Group 1001 Pennsylvania Ave. Nw, Suite 220S Washington DC 20004-2505	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Voting Common Stock	Acquisiton	2024-02-08	190,000	$12.95	1,066,189	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Footnotes

The amount of Voting Common Stock reported herein reflects a 1-for-10 reverse stock split effected by the Issuer on January 4, 2024.
Reflects securities held of record by Abingworth Bioventures VII LP ("ABV VII"). ABV VII has delegated to Abingworth LLP all investment and dispositive power over the securities held of record by ABV VII.
The Carlyle Group Inc., which is a publicly traded entity listed on Nasdaq, is the sole shareholder of Carlyle Holdings I GP Inc., which is the sole member of Carlyle Holdings I GP Sub L.L.C., which is the general partner of Carlyle Holdings I L.P., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the managing member of TC Group, L.L.C., which is the managing member of Carlyle Investment Management, L.L.C., which is the sole member of Carlyle Genesis UK LLC, which is the principal member of Abingworth LLP. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by ABV VII, but each disclaims beneficial ownership of such securities except to the extent of their pecuniary interest therein, if any.